[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kura Oncology (KURA)

Kura Oncology (KURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 948,106
  • Shares Outstanding, K 88,774
  • Annual Sales, $ 67,480 K
  • Annual Income, $ -278,670 K
  • EBIT $ -318 M
  • EBITDA $ -325 M
  • 60-Month Beta 0.35
  • Price/Sales 14.29
  • Price/Cash Flow N/A
  • Price/Book 8.94

Options Overview Details

View History
  • Implied Volatility 141.75% (+27.68%)
  • Historical Volatility 47.89%
  • IV Percentile 56%
  • IV Rank 24.66%
  • IV High 434.09% on 02/04/26
  • IV Low 46.05% on 05/19/26
  • Expected Move (DTE 31) 0.51 (4.73%)
  • Put/Call Vol Ratio 0.63
  • Today's Volume 1,090
  • Volume Avg (30-Day) 1,144
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 4,219
  • Open Int (30-Day) 8,462
  • Expected Range 10.27 to 11.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.89
  • Number of Estimates 4
  • High Estimate $-0.81
  • Low Estimate $-1.02
  • Prior Year $-0.75
  • Growth Rate Est. (year over year) -18.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.95 +8.89%
on 06/22/26
12.22 -11.33%
on 07/09/26
+0.90 (+9.11%)
since 06/18/26
3-Month
8.39 +29.14%
on 06/08/26
12.22 -11.33%
on 07/09/26
+1.36 (+14.41%)
since 04/21/26
52-Week
5.45 +98.81%
on 08/11/25
12.49 -13.25%
on 11/14/25
+4.37 (+67.47%)
since 07/21/25

Most Recent Stories

More News
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients – – Updated data expected to support...

KURA : 10.85 (+1.59%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 10.85 (+1.59%)
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial – – 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r...

KURA : 10.85 (+1.59%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 10.85 (+1.59%)
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve...

KURA : 10.85 (+1.59%)
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responders...

KURA : 10.85 (+1.59%)
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve...

KURA : 10.85 (+1.59%)
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) today announced its participation in the TD Cowen 7 th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Kura...

KURA : 10.85 (+1.59%)
Kura Oncology Q1 Earnings Call Highlights

Kura Oncology (NASDAQ:KURA) reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is showing early signs of physician uptake, broad...

KURA : 10.85 (+1.59%)
Kura Oncology: Q1 Earnings Snapshot

Kura Oncology: Q1 Earnings Snapshot

KURA : 10.85 (+1.59%)

Business Summary

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL,...

See More

Key Turning Points

3rd Resistance Point 11.49
2nd Resistance Point 11.33
1st Resistance Point 11.00
Last Price 10.85
1st Support Level 10.51
2nd Support Level 10.35
3rd Support Level 10.02

See More

52-Week High 12.49
Last Price 10.85
Fibonacci 61.8% 9.80
Fibonacci 50% 8.97
Fibonacci 38.2% 8.14
52-Week Low 5.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.